• 1
    Yudkin JS, Beran D. Prognosis of diabetes in the developing world. Lancet 2003; 362: 1420.
  • 2
    Roper NA, Bilous RW, Kelly WF et al. Cause-specific mortality in a population with diabetes. South Tees Diabetes Mortality Study. Diabetes Care 2002; 25: 4348.
  • 3
    Mocroft A, Brettle R, Kirk O et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 16631671.
  • 4
    Thio CL, Seaberg EC, Skolasky R et al. Liver disease mortality in HIV-HBV co-infected persons. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, 2002 [Abstract 656].
  • 5
    Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. The Multivirc Group. Hepatol 1999; 30: 10541058.
  • 6
    Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 15.
  • 7
    Rockstroh J, Konopnicki D, Soriano V et al. Hepatitis B and Hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS progression and response to HAART. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2004 [Abstract 799].
  • 8
    Beck EJ, Mandalia S, Leonard K et al. Case-control study of sexually transmitted diseases as cofactors for HIV-1 transmission. Int J STD AIDS 1996; 7: 3438.
  • 9
    Rudge CJ, Fuggle SV, Burbidge KM. Geographic disparities in access to organ transplantation in the United Kingdom. Transplantation 2003; 76: 13951398.
  • 10
    Devlin J, O-Grady J. Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. Gut 1999; 45 (Suppl. 6): VI1VI22.
  • 11
    Neuberger J, James O. Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage. Lancet 1999; 354: 16361639.
  • 12
    Soriano V, Miró JM, García SJ et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 2004; 11: 217.
  • 13
    Ragni MV, Belle SH, Im-Kyung AH et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 14121420.
  • 14
    Fung J, Eghtesad B, Patel TK et al. Liver transplantation in patients with HIV infection. Liver Transpl 2004; 10 (Suppl. 2): S39S53.
  • 15
    Norris S, Taylor C, Muiesan P et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004; 10: 12711278.
  • 16
    Neff G, Bonham A, Tzakis AG et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239247.
  • 17
    Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003; 75: 425429.
  • 18
    Adam R, McMaster PO, -Grady JG et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 12311243.
  • 19
    Neuberger J. Hope or efficacy in donor liver allocation? Transplantation 2001; 72: 11731176.
  • 20
    Everhart JE, Lombardero M, Detre KM et al. Increased waiting time for liver transplantation results in higher mortality. Transplantation 1997; 64: 13001306.
  • 21
    Ravaioli M, Ercolani G, Cescon M et al. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl 2004; 10: 11951202.
  • 22
    Fernández JA, Robles R, Marin C et al. Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? Transplant Proc 2003; 35: 18181820.
  • 23
    Mela M, Mancuso A, Burroughs AK. Hepatocellular carcinoma: indications for liver transplantation. Aliment Pharmacol Ther 2003; 17 (Suppl. 2): 130137.
  • 24
    Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: 765774.
  • 25
    Fisher RA, Maluf D, Cotterell AH et al. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant 2004; 18: 502512.
  • 26
    Wong LL, Tanaka K, Lau L et al. Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. Clin Transplant 2004; 18: 227234.
  • 27
    Takamori R, Wong LL, Dang C et al. Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary? Liver Transpl 2000; 6: 6772.
  • 28
    Caturelli E, Ghittoni G, Roselli P et al. Fine needle biopsy of focal liver lesions: the hepatologist's point of view. Liver Transpl 2004; 10 (Suppl. 1): S26S29.
  • 29
    Jain AKB, Venkataramanan R, Shapiro R et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8: 841845.
  • 30
    Casanovas TT. Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation. Transplant Proc 2004; 36 (2 Suppl.): 291S294S.
  • 31
    Bravata DM, Olkin I, Barnato AE et al. Health-related quality of life after liver transplantation: a meta-analysis. Liver Transpl Surg 1999; 5: 318331.
  • 32
    Blanch J, Sureda B, Flavia M et al. Psychosocial adjustment to orthotopic liver transplantation in 266 recipients. Liver Transpl 2004; 10: 228234.